{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:57:52Z","timestamp":1762865872849},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.antiviral.2011.08.013","type":"journal-article","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T03:19:04Z","timestamp":1315365544000},"page":"382-385","source":"Crossref","is-referenced-by-count":20,"title":["Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, na\u00efve to antiviral drugs"],"prefix":"10.1016","volume":"92","author":[{"given":"R.","family":"Salpini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Svicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Cento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Scopelliti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Micheli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Cappiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Span\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Rizzardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.M.","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sarrecchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Angelico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.F.","family":"Perno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2011.08.013_b0005","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hep.22790","article-title":"The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains","volume":"49","author":"Amini-Bavil-Olyaee","year":"2009","journal-title":"Hepatology;"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2011.08.013_b0010","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1002\/jmv.20608","article-title":"Hepatitis B virus mutations associated with antiviral therapy","volume":"78","author":"Bartholomeusz","year":"2006","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrgastro.2009.107","article-title":"Hepatitis B virus variants","volume":"6","author":"Chotiyaputta","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.virol.2007.03.015","article-title":"High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus","volume":"365","author":"De Maddalena","year":"2007","journal-title":"Virology"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2011.08.013_b0025","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S1386-6532(05)80008-3","article-title":"Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing","volume":"34","author":"Durantel","year":"2005","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0030","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1053\/j.gastro.2007.02.039","article-title":"Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B","volume":"132","author":"Ghany","year":"2007","journal-title":"Gastroenterology"},{"issue":"5 Suppl.","key":"10.1016\/j.antiviral.2011.08.013_b0035","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/hep.22900","article-title":"Antiviral resistance and hepatitis B therapy","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2011.08.013_b0040","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1440-1746.2009.05864.x","article-title":"Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients","volume":"24","author":"Han","year":"2009","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0045","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2008.08.021","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update","volume":"6","author":"Keeffe","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0050","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/S0168-8278(11)60733-2","article-title":"Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 302 nuc-na\u00efve patients with chronic hepatitis B","volume":"54","author":"Lampertico","year":"2011","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2011.08.013_b0055","first-page":"S389","article-title":"Effectiveness of entecavir for NUC-naive, HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients","volume":"52","author":"Lampertico","year":"2011","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2011.08.013_b0060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-1746.2010.06541.x","article-title":"The clinical implications of hepatitis B virus genotype: recent advances","volume":"26","author":"Lin","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12072-008-9048-3","article-title":"Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure","volume":"2","author":"Locarnini","year":"2008","journal-title":"Hepatol. Int."},{"issue":"Suppl. 3","key":"10.1016\/j.antiviral.2011.08.013_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3851\/IMP1619","article-title":"Molecular genetics of HBV infection","volume":"15","author":"Locarnini","year":"2010","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2011.08.013_b0075","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management","volume":"46","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2011.08.013_b0080","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.antiviral.2009.12.006","article-title":"Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-na\u00efve Chinese patients","volume":"85","author":"Liu","year":"2010","journal-title":"Antiviral. Res."},{"key":"10.1016\/j.antiviral.2011.08.013_b0085","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1086\/597808","article-title":"Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients","volume":"199","author":"Margeridon-Thermet","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.08.013_b0090","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12072-008-9112-z","article-title":"The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B","volume":"3","author":"McMahon","year":"2009","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2011.08.013_b0095","first-page":"5","article-title":"Diagnosis and treatment of chronic hepatitis B: 2009 update","volume":"55","author":"Morgan","year":"2009","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0100","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/gast.1997.v113.pm9322520","article-title":"Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study","volume":"113","author":"Nevens","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2011.08.013_b0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2893.2009.01078.x","article-title":"Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides","volume":"16","author":"Nguyen","year":"2009","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2011.08.013_b0110","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1128\/JCM.00045-09","article-title":"Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology","volume":"47","author":"Ntziora","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0115","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3748\/wjg.15.753","article-title":"Hepatitis B virus mutations potentially conferring adefovir\/tenofovir resistance in treatment-naive patients","volume":"15","author":"Pastor","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0120","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/135965350901400504","article-title":"Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients","volume":"14","author":"Pollicino","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2011.08.013_b0125","first-page":"177","article-title":"Tenofovir and its potential in the treatment of hepatitis B virus","volume":"5","author":"Reynaud","year":"2009","journal-title":"Ther. Clin. Risk. Manag."},{"key":"10.1016\/j.antiviral.2011.08.013_b0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2893.2009.01149.x","article-title":"Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B","volume":"17","author":"Sayan","year":"2010","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2011.08.013_b0135","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/135965350501000612","article-title":"Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir","volume":"10","author":"Sheldon","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2011.08.013_b0140","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2893.2005.00713.x","article-title":"Mutations affecting the replication capacity of the hepatitis B virus","volume":"13","author":"Sheldon","year":"2006","journal-title":"J. Viral. Hepat."},{"issue":"Suppl. 7","key":"10.1016\/j.antiviral.2011.08.013_b0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0213-005X(08)76519-4","article-title":"Resistance in hepatitis B virus","volume":"26","author":"Sheldon","year":"2008","journal-title":"Enferm. Infec. Microbiol. Clin."},{"key":"10.1016\/j.antiviral.2011.08.013_b0150","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1128\/JCM.01073-09","article-title":"Selection and counter selection of the rtI233V adefovir resistance mutation during antiviral therapy","volume":"48","author":"Schildgen","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0155","first-page":"1","article-title":"Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients","volume":"9","author":"Shin","year":"2003","journal-title":"Taehan Kan Hakhoe Chi."},{"key":"10.1016\/j.antiviral.2011.08.013_b0160","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1128\/JVI.02011-08","article-title":"Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen","volume":"83","author":"Solmone","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0165","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.dld.2010.04.017","article-title":"Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia","volume":"42","author":"Svicher","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.antiviral.2011.08.013_b0170","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2008.01.027","article-title":"Impact of hepatitis B virus rtA181V\/T mutants on hepatitis B treatment failure","volume":"48","author":"Villet","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0175","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1128\/JCM.43.5.2503-2505.2005","article-title":"Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy","volume":"43","author":"Z\u00f6llner","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2011.08.013_b0180","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211004141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211004141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T07:02:09Z","timestamp":1686294129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354211004141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0166354211004141"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2011.08.013","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}